June 3 (Reuters) - Dutch and Swiss chemicals maker DSM-Firmenich expects to reach an adjusted EBITDA margin of 22-23% for its mid-term targets, it said on Monday.

"Demand for fragrances and beauty products has surged, with scent being a key purchase driver," said CEO Dimitri de Vreeze.

The company reported an adjusted EBITDA margin of 15.1% in the first quarter.

DSM-Firmenich also said it sees organic sales growth of between 5% and 7% and cash-to-sales conversion of over 10%.

After a disappointing 2023 following low vitamin prices, the company said in May it expects the trend to reverse into the year.

On Monday, DSM-Firmenich said it was planning to de-prioritise certain business segments, echoeing comments made in February about carving out its struggling animal supplements business in 2025. (Reporting by Dimitri Rhodes and Matteo Allievi; Editing by Muralikumar Anantharaman)